2. Search Result
Search Result
Isoforms Recommended: Tyro3
Results for "

Tyro3

" in MedChemExpress (MCE) Product Catalog:

20

Inhibitors & Agonists

1

Fluorescent Dye

1

Biochemical Assay Reagents

1

Inhibitory Antibodies

6

Recombinant Proteins

2

Antibodies

3

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-124502
    UNC4203

    		TAM Receptor FLT3 Cancer
    UNC4203 is a potent, orally available and highly selective MERTK inhibitor, with IC50s of 1.2 nM, 140 nM, 42 nM and 90 nM for MERTK, AXL, TYRO3 and FLT3, respectively .
    UNC4203
  • HY-12494
    LDC1267
    5+ Cited Publications

    		 TAM Receptor Inflammation/Immunology Cancer
    LDC1267 is a highly selective TAM (Tyro3, Axl and Mer) kinase inhibitor with IC50s of <5 nM/8 nM/29 nM for Tyro3,Axl and Mer respectively .
    LDC1267
  • HY-117596
    UNC569
    1 Publications Verification

    		 TAM Receptor Cancer
    UNC569 is a potent, reversible, ATP-competitive and orally active Mer kinase inhibitor with an IC50 of 2.9 nM and a Ki of 4.3 nM. UNC569 also inhibits Axl and Tyro3 with IC50s of 37 nM and 48 nM, respectively. UNC569 can be used for acute lymphoblastic leukemia (ALL) and atypical teratoid/rhabdoid tumors research
    UNC569
  • HY-15797
    UNC2250
    2 Publications Verification

    		 TAM Receptor Cancer
    UNC2250 is a potent and selective Mer inhibitor with an IC50 of 1.7 nM, about 160- and 60-fold selectivity over the closely related kinases Axl/Tyro3.
    UNC2250
  • HY-147218
    PF-07265807

    		c-Met/HGFR TAM Receptor Cancer
    PF-07265807 is a potent TAM and c-Met kinase inhibitor with IC50 values of 6.1 nM, 13.2 nM and 21.6 nM for AXL, MER and TYRO3, respectively. PF-07265807 can be used for researching anticancer .
    PF-07265807
  • HY-RS17427
    Tyro3 Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Tyro3 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Tyro3 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Tyro3 Mouse Pre-designed siRNA Set A
    Tyro3 Mouse Pre-designed siRNA Set A
  • HY-RS23882
    Tyro3 Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Tyro3 Rat Pre-designed siRNA Set A contains three designed siRNAs for Tyro3 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Tyro3 Rat Pre-designed siRNA Set A
    Tyro3 Rat Pre-designed siRNA Set A
  • HY-RS15308
    TYRO3 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    TYRO3 Human Pre-designed siRNA Set A contains three designed siRNAs for TYRO3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    TYRO3 Human Pre-designed siRNA Set A
    TYRO3 Human Pre-designed siRNA Set A
  • HY-173268
    UNC9426

    		TAM Receptor Cardiovascular Disease Cancer
    UNC9426 (compound 12) is a potent, orally bioavailable and specific TYRO3 inhibitor with an IC50 of 2.1 nM. UNC9426 reduces platelet aggregation without increasing bleeding time. UNC9426 blocks TYRO3-dependent functions in tumor cells and macrophages .
    UNC9426
  • HY-172796
    UNC9435

    		TAM Receptor Cancer
    UNC9435 (compound 44) is a dual inhibitor of TYRO3/MERTK with IC50 values of 3.7 nM and 1.1 nM, respectively. UNC9435 reduces colony formation in non-small cell lung cancer cultures
    UNC9435
  • HY-173400
    UNC8212

    		TAM Receptor Cancer
    UNC8212 is a TAM kinase inhibitor. UNC8212 has potent inhibitory activity against MERTK and AXL (IC50: 1.5 nM and 1.3 nM, respectively), and also inhibits TYRO3 (IC50: 6.7 nM). UNC8212 mediates polypharmacological properties by targeting the structurally diverse "back pocket" region of the TAM kinase family. UNC8212 binds tightly to TAM kinases and potently inhibits MERTK and AXL phosphorylation. UNC8212 has anti-tumor effects and can be used in cancer immunotherapy and tumor cell targeting research .
    UNC8212
  • HY-132200
    UNC5293

    		TAM Receptor Anaplastic lymphoma kinase (ALK) FLT3 Cancer
    UNC5293 is a MERTK-selective and potent inhibitor (Ki=190 pM). UNC5293 inhibits MERTK (IC50=0.9 nM) and is more selective over Axl, Tyro3 and Flt3. UNC5293 exhibits excellent mouse PK properties and is used for bone marrow leukemia research .
    UNC5293
  • HY-125510
    UNC2541
    1 Publications Verification

    		 TAM Receptor Neurological Disease Inflammation/Immunology
    UNC2541 is a potent and Mer tyrosine kinase (MerTK)-specific inhibitor, binds in the MerTK ATP pocket, with an IC50 of 4.4 nM, more selective over Axl, Tyro3 and Flt3. UNC2541 inhibits phosphorylated MerTK (pMerTK; EC50, 510 nM). UNC2541 abolishes the analgesic and anti-inflammatory effects of ozone in vivo and in vitro [3].
    UNC2541
  • HY-116000
    Glumetinib
    1 Publications Verification

    Gumarontinib; SCC244

    		 c-Met/HGFR Cancer
    Glumetinib (SCC244) is a highly selective, orally bioavailable, ATP-competitive c-Met inhibitor with an IC50 of 0.42 nM. Glumetinib has greater than 2400-fold selectivity for c-Met over those 312 kinases evaluated, including the c-Met family member RON and highly homologous kinases Axl, Mer, TyrO3. Antitumor activity .
    Glumetinib
  • HY-15150
    Bemcentinib
    Maximum Cited Publications
    47 Publications Verification

    R428; BGB324

    		 TAM Receptor Cancer
    Bemcentinib (R428) is a selective and orally active Axl inhibitor with an IC50 of 14 nM. Bemcentinib retards cancer cell migration and invasion. Bemcentinib exhibits >100-fold selectivity for Axl versus Abl and 50- and >100-fold selectivity over TAM family kinases Mer and Tyro3, respectively, in cells. Bemcentinib blocks tumor spread and prolongs survival in models of metastatic breast cancer .
    Bemcentinib
  • HY-12076
    BMS 777607
    10+ Cited Publications

    BMS 817378

    		 c-Met/HGFR TAM Receptor Cancer
    BMS 777607 (BMS 817378) is a Met-related inhibitor for c-Met, Axl, Ron and Tyro3 with IC50s of 3.9 nM, 1.1 nM, 1.8 nM and 4.3 nM, respectively, and 40-fold more selective for Met-related targets than Lck, VEGFR-2, and TrkA/B, with more than 500-fold greater selectivity versus all other receptor and non receptor kinases .
    BMS 777607
  • HY-147695
    c-Met-IN-12

    		c-Met/HGFR Cancer
    c-Met-IN-12 (compound 4r) is an orally active, potent and selective type II c-Met kinase inhibitor, with an IC50 of 10.6 nM. c-Met-IN-12 displays high inhibitory effects (inhibition rate > 80% in 1 μM) against AXL, Mer and TYRO3 kinases. c-Met-IN-12 can be used a scaffold for further kinase selectivity enhancement. c-Met-IN-12 shows antitumor efficacy .
    c-Met-IN-12
  • HY-117548
    UNC1062
    1 Publications Verification

    		 TAM Receptor Cancer
    UNC1062 is a MERTK-selective tyrosine kinase inhibitor, reduces activation of MERTK-mediated downstream signaling, induces apoptosis in culture, reduces colony formation in soft agar, and inhibits invasion of melanoma cells. UNC1062 potently inhibits MERTK kinase activity (MERTK IC50=1.1 nM, Morrison Ki=0.33 nM) and exhibits specificity within the TAM family (TYRO3 IC50=60 nM, AXL IC50=85 nM) .
    UNC1062
  • HY-15150G
    Bemcentinib (GMP)

    R428 (GMP); BGB324 (GMP)

    		 TAM Receptor Cancer
    Bemcentinib (R428) GMP is Bemcentinib (HY-15150) in GMP grade. GMP-grade small molecules can be used as auxiliary reagents in cell therapy.Bemcentinib (R428) is a selective and orally active Axl inhibitor with an IC50 of 14 nM. Bemcentinib retards cancer cell migration and invasion. Bemcentinib exhibits >100-fold selectivity for Axl versus Abl and 50- and >100-fold selectivity over TAM family kinases Mer and Tyro3, respectively, in cells. Bemcentinib blocks tumor spread and prolongs survival in models of metastatic breast cancer .
    Bemcentinib (GMP)
  • HY-162085
    Axl-IN-17

    		TAM Receptor Cancer
    Axl-IN-17 (compound 13c) is an orally active, selective AXL inhibitor with an IC50 value of 3.2 nM. Axl-IN-17 reveals antitumor efficacy .
    Axl-IN-17

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: